GlassScriptPhysician profile
Feroz A Osmani
NPI 1780180190
$31,588.45
in general payments reported to CMS, 2019-2025
21 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20K · 2023: $5,381 · 2024: $2,710 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,689 · Travel and Lodging: $2,595 · Consulting Fee: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,688.51 |
| Travel and Lodging | $2,594.88 |
| Consulting Fee | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21,040.65 | 2022-2025 | Superion Indirect Decompression System, Intracept, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $6,264.75 | 2023-2025 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $1,537.69 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Osteocool Rf Ablation System |
| Nevro Corp. | $608.29 | 2023 | Senza |
| Nalu Medical, INC. | $327.79 | 2024-2025 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $323.25 | 2023-2024 | Evoke Scs, Evoke |
| Spr Therapeutics, INC | $262.19 | 2023-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $250.69 | 2023-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $200.04 | 2025 | Senza |
| Abbvie INC. | $150.39 | 2025 | |
| Zynex Medical, INC. | $140.31 | 2025 | Nexwave |
| Pfizer INC. | $132.95 | 2025 | |
| Si-Bone, INC. | $101.90 | 2025 | |
| Stryker Corporation | $51.23 | 2023 | Spinejack |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.21 | 2024 | Relistor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $37.87 | 2025 | Qutenza |
| Vertos Medical, INC. | $33.33 | 2023 | Mild Device Kit |
| Vertex Pharmaceuticals Incorporated | $22.45 | 2025 | |
| Curonix LLC | $20.95 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ibsa Pharma INC. | $19.00 | 2023 | Tirosint, Licart |
| Pacira Pharmaceuticals Incorporated | $17.52 | 2023 | Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feroz Osmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.